Dariusz Olszewski, Aneta Tomaszewska, Bolesław Samolinski
{"title":"Factors influencing patients' decisions regarding participation in clinical trials: Review of current literature.","authors":"Dariusz Olszewski, Aneta Tomaszewska, Bolesław Samolinski","doi":"10.17219/acem/190453","DOIUrl":null,"url":null,"abstract":"<p><p>Obtaining timely data in clinical trials (CTs) is critical for drug registration. This depends directly on the speed at which patients are recruited. This paper provides an overview of selected scientific works and literature from different countries about patients' motivators and barriers to participating in CTs From 55 articles retrieved from PubMed, 5 were selected for the analysis. Additionally, 6 publications, including 2 by Polish authors, were reviewed. As a result, we identified 10 factors for further investigation: altruism, hope for personal benefit, access to better care, the role of a doctor, the opinions of close friends or relatives, financial compensation, side effects, the patient's role as a guinea pig, effort and time, and the use of placebo. Regardless of the therapeutic area, health status, study phase, country, geographic area, economic situation, or healthcare system, patients indicated very similar reasons when deciding to participate in a CT. Even if patients as a group had similar motives and concerns, there are individual elements or unusual factors that need to be better understood and evaluated to accelerate the recruitment process in order to avoid certain drugs or therapies being overlooked or underestimated. In this way, investigators can help patients make the best decisions and more effectively support the process of registering a new drug. Future research on factors influencing patients' decisions is still necessary: We do not know how the COVID-19 pandemic may have influenced patient motivation, how new regulations on CTs are changing patients' perceptions of CTs, and what may be important depending on the study, country, therapeutic area and other factors.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17219/acem/190453","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Obtaining timely data in clinical trials (CTs) is critical for drug registration. This depends directly on the speed at which patients are recruited. This paper provides an overview of selected scientific works and literature from different countries about patients' motivators and barriers to participating in CTs From 55 articles retrieved from PubMed, 5 were selected for the analysis. Additionally, 6 publications, including 2 by Polish authors, were reviewed. As a result, we identified 10 factors for further investigation: altruism, hope for personal benefit, access to better care, the role of a doctor, the opinions of close friends or relatives, financial compensation, side effects, the patient's role as a guinea pig, effort and time, and the use of placebo. Regardless of the therapeutic area, health status, study phase, country, geographic area, economic situation, or healthcare system, patients indicated very similar reasons when deciding to participate in a CT. Even if patients as a group had similar motives and concerns, there are individual elements or unusual factors that need to be better understood and evaluated to accelerate the recruitment process in order to avoid certain drugs or therapies being overlooked or underestimated. In this way, investigators can help patients make the best decisions and more effectively support the process of registering a new drug. Future research on factors influencing patients' decisions is still necessary: We do not know how the COVID-19 pandemic may have influenced patient motivation, how new regulations on CTs are changing patients' perceptions of CTs, and what may be important depending on the study, country, therapeutic area and other factors.
期刊介绍:
Advances in Clinical and Experimental Medicine has been published by the Wroclaw Medical University since 1992. Establishing the medical journal was the idea of Prof. Bogumił Halawa, Chair of the Department of Cardiology, and was fully supported by the Rector of Wroclaw Medical University, Prof. Zbigniew Knapik. Prof. Halawa was also the first editor-in-chief, between 1992-1997. The journal, then entitled "Postępy Medycyny Klinicznej i Doświadczalnej", appeared quarterly.
Prof. Leszek Paradowski was editor-in-chief from 1997-1999. In 1998 he initiated alterations in the profile and cover design of the journal which were accepted by the Editorial Board. The title was changed to Advances in Clinical and Experimental Medicine. Articles in English were welcomed. A number of outstanding representatives of medical science from Poland and abroad were invited to participate in the newly established International Editorial Staff.
Prof. Antonina Harłozińska-Szmyrka was editor-in-chief in years 2000-2005, in years 2006-2007 once again prof. Leszek Paradowski and prof. Maria Podolak-Dawidziak was editor-in-chief in years 2008-2016. Since 2017 the editor-in chief is prof. Maciej Bagłaj.
Since July 2005, original papers have been published only in English. Case reports are no longer accepted. The manuscripts are reviewed by two independent reviewers and a statistical reviewer, and English texts are proofread by a native speaker.
The journal has been indexed in several databases: Scopus, Ulrich’sTM International Periodicals Directory, Index Copernicus and since 2007 in Thomson Reuters databases: Science Citation Index Expanded i Journal Citation Reports/Science Edition.
In 2010 the journal obtained Impact Factor which is now 1.179 pts. Articles published in the journal are worth 15 points among Polish journals according to the Polish Committee for Scientific Research and 169.43 points according to the Index Copernicus.
Since November 7, 2012, Advances in Clinical and Experimental Medicine has been indexed and included in National Library of Medicine’s MEDLINE database. English abstracts printed in the journal are included and searchable using PubMed http://www.ncbi.nlm.nih.gov/pubmed.